Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
CollPlant Biotechnologies Ltd is a biotechnology business based in the US. CollPlant Biotechnologies shares (CLGN) are listed on the NASDAQ and all prices are listed in US Dollars. CollPlant Biotechnologies employs 52 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$20.00|
|52-week range||$6.19 - $24.26|
|50-day moving average||$16.89|
|200-day moving average||$16.91|
|Wall St. target price||$23.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||N/A|
|1 month (2021-09-19)||N/A|
|3 months (2021-07-23)||12.93%|
|6 months (2021-04-23)||37.17%|
|1 year (2020-10-23)||186.53%|
|2 years (2019-10-23)||344.44%|
|3 years (2018-10-23)||214.96%|
|5 years (2016-10-19)||N/A|
Valuing CollPlant Biotechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CollPlant Biotechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CollPlant Biotechnologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, CollPlant Biotechnologies shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CollPlant Biotechnologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.1 million.
The EBITDA is a measure of a CollPlant Biotechnologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$19.9 million|
|Operating margin TTM||27.11%|
|Gross profit TTM||$3.1 million|
|Return on assets TTM||10.22%|
|Return on equity TTM||17.69%|
|Market capitalisation||$167.3 million|
TTM: trailing 12 months
There are currently 12,979 CollPlant Biotechnologies shares held short by investors – that's known as CollPlant Biotechnologies's "short interest". This figure is 15.8% up from 11,206 last month.
There are a few different ways that this level of interest in shorting CollPlant Biotechnologies shares can be evaluated.
CollPlant Biotechnologies's "short interest ratio" (SIR) is the quantity of CollPlant Biotechnologies shares currently shorted divided by the average quantity of CollPlant Biotechnologies shares traded daily (recently around 11799.090909091). CollPlant Biotechnologies's SIR currently stands at 1.1. In other words for every 100,000 CollPlant Biotechnologies shares traded daily on the market, roughly 1100 shares are currently held short.
However CollPlant Biotechnologies's short interest can also be evaluated against the total number of CollPlant Biotechnologies shares, or, against the total number of tradable CollPlant Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CollPlant Biotechnologies's short interest could be expressed as 0% of the outstanding shares (for every 100,000 CollPlant Biotechnologies shares in existence, roughly 0 shares are currently held short) or 0.0013% of the tradable shares (for every 100,000 tradable CollPlant Biotechnologies shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CollPlant Biotechnologies.
Find out more about how you can short CollPlant Biotechnologies stock.
We're not expecting CollPlant Biotechnologies to pay a dividend over the next 12 months.
CollPlant Biotechnologies's shares were split on a 2:3 basis on 20 November 2016. So if you had owned 3 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your CollPlant Biotechnologies shares – just the quantity. However, indirectly, the new 50% higher share price could have impacted the market appetite for CollPlant Biotechnologies shares which in turn could have impacted CollPlant Biotechnologies's share price.
Over the last 12 months, CollPlant Biotechnologies's shares have ranged in value from as little as $6.185 up to $24.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CollPlant Biotechnologies's is 0.7772. This would suggest that CollPlant Biotechnologies's shares are less volatile than average (for this exchange).
CollPlant Biotechnologies Ltd. , a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.